Compare · CG vs HQL
CG vs HQL
Side-by-side comparison of The Carlyle Group Inc. (CG) and abrdn Life Sciences Investors Shares of Beneficial Interest (HQL): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CG and HQL operate in Investment Managers (Finance), so they compete in similar markets.
- CG is the larger of the two at $15.68B, about 36.6x HQL ($428.1M).
- Over the past year, CG is down 6.5% and HQL is up 29.8% - HQL leads by 36.2 points.
- CG has been more active in the news (13 items in the past 4 weeks vs 2 for HQL).
- CG has more recent analyst coverage (25 ratings vs 0 for HQL).
- Company
- The Carlyle Group Inc.
- abrdn Life Sciences Investors Shares of Beneficial Interest
- Price
- $43.57+0.22%
- $16.65-1.39%
- Market cap
- $15.68B
- $428.1M
- 1M return
- -11.08%
- -7.24%
- 1Y return
- -6.46%
- +29.77%
- Industry
- Investment Managers
- Investment Managers
- Exchange
- NASDAQ
- NYSE
- IPO
- 2012
- 1992
- News (4w)
- 13
- 2
- Recent ratings
- 25
- 0
The Carlyle Group Inc.
The Carlyle Group Inc. is an investment firm specializing in direct and fund of fund investments. Within direct investments, it specializes in management-led/ Leveraged buyouts, privatizations, divestitures, strategic minority equity investments, structured credit, global distressed and corporate opportunities, small and middle market, equity private placements, consolidations and buildups, senior debt, mezzanine and leveraged finance, and venture and growth capital financings, seed/startup, early venture, emerging growth, turnaround, mid venture, late venture, PIPES. The firm invests across four segments which include Corporate Private Equity, Real Assets, Global Market Strategies, and Solutions. The firm typically invests in industrial, agribusiness, ecological sector, fintech, airports, parking, Plastics, Rubber, diversified natural resources, minerals, farming, aerospace, defense, automotive, consumer, retail, industrial, infrastructure, energy, power, healthcare, software, software enabled services, semiconductors, communications infrastructure, financial technology, utilities, gaming, systems and related supply chain, electronic systems, systems, oil and gas, processing facilities, power generation assets, technology, systems, real estate, financial services, transportation, business services, telecommunications, media, and logistics sectors. Within the industrial sector, the firm invests in manufacturing, building products, packaging, chemicals, metals and mining, forestry and paper products, and industrial consumables and services. In consumer and retail sectors, it invests in food and beverage, retail, restaurants, consumer products, domestic consumption, consumer services, personal care products, direct marketing, and education. Within aerospace, defense, business services, and government services sectors, it seeks to invest in defense electronics, manufacturing and services, government contracting and services, information technology, distribution companies. In telecommunication and media sectors, it invests in cable TV, directories, publishing, entertainment and content delivery services, wireless infrastructure/services, fixed line networks, satellite services, broadband and Internet, and infrastructure. Within real estate, the firm invests in office, hotel, industrial, retail, for sale residential, student housing, hospitality, multifamily residential, homebuilding and building products, and senior living sectors. The firm seeks to make investments in growing business including those with overleveraged balance sheets. The firm seeks to hold its investments for four to six years. In the healthcare sector, it invests in healthcare services, outsourcing services, companies running clinical trials for pharmaceutical companies, managed care, pharmaceuticals, pharmaceutical related services, healthcare IT, medical, products, and devices. It seeks to invest in companies based in Sub-Saharan focusing on Ghana, Kenya, Mozambique, Botswana, Nigeria, Uganda, West Africa, North Africa and South Africa focusing on Tanzania and Zambia; Asia focusing on Pakistan, India, South East Asia, Indonesia, Philippines, Vietnam, Korea, and Japan; Australia; New Zealand; Europe focusing on France, Italy, Denmark, United Kingdom, Germany, Austria, Belgium, Finland, Iceland, Ireland, Netherlands, Norway, Portugal, Spain, Benelux , Sweden, Switzerland, Hungary, Poland, and Russia; Middle East focusing on Bahrain, Jordan, Kuwait, Lebanon, Oman, Qatar, Saudi Arabia, Turkey, and UAE; North America focusing on United States which further invest in Southeastern United States, Texas, Boston, San Francisco Bay Area and Pacific Northwest; Asia Pacific; Soviet Union, Central-Eastern Europe, and Israel; Nordic region; and South America focusing on Mexico, Argentina, Brazil, Chile, and Peru. The firm seeks to invest in food, financial, and healthcare industries in Western China. In the real estate sector, the firm seeks to invest in various locations across Europe focusing on France and Central Europe, United States, Asia focusing on China, and Latin America. It typically invests between $1 million and $50 million for venture investments and between $20 million and $1 billion for buyouts in companies with enterprise value of between $31.57 million and $1000 million and sales value of $10 million and $500 million. It seeks to invest in companies with market capitalization greater than $50 million and EBITDA between $5 million to $25 million. It prefers to take a majority stake. It typically holds its investments for three to five years. Within automotive and transportation sectors, the firm seeks to hold its investments in for four to six years. While investing in Japan, it does not invest in companies with more than 1,000 employees and prefers companies' worth between $100 million and $150 million. The firm originates, structures, and acts as lead equity investor in the transactions. The Carlyle Group Inc. was founded in 1987 and is
abrdn Life Sciences Investors Shares of Beneficial Interest
Tekla Life Sciences Investors is a closed-ended equity mutual fund launched and managed by Tekla Capital Management LLC. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries. The fund primarily invests in growth stocks of small cap companies. It employs fundamental analysis with a focus on factors such as market position for services or products, experience of business management, technological expertise, and the ability either to generate funds internally to finance growth or to secure outside sources of capital to create its portfolio. The fund benchmarks the performance of its portfolio against the NASDAQ Biotech Index and the S&P 500 Index. It was formerly known as H&Q Life Sciences Investors fund. Tekla Life Sciences Investors was formed on February 20, 1992 and is domiciled in the United States.
Latest CG
- Carlyle Completes Acquisition of Majority Stake in MAI Capital Management
- The Carlyle Group Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- ModelFront Announces Outcome-Based Pricing
- The Carlyle Group Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- Chief Operating Officer Lobue Lindsay was granted 3,120 shares, increasing direct ownership by 0.44% to 716,205 units (SEC Form 4)
- Co-President Jenkins Mark David was granted 7,634 shares, increasing direct ownership by 0.50% to 1,534,007 units (SEC Form 4)
- Chief Financial Officer Plouffe Justin was granted 4,077 shares, increasing direct ownership by 0.45% to 911,225 units (SEC Form 4)
- Chief Accounting Officer Andrews Charles Elliott Jr. was granted 409 shares, increasing direct ownership by 0.28% to 147,728 units (SEC Form 4)
- Co-President Nedelman Jeffrey was granted 7,733 shares, increasing direct ownership by 0.47% to 1,645,945 units (SEC Form 4)
- General Counsel Ferguson Jeffrey W. was granted 1,274 shares, increasing direct ownership by 0.16% to 783,474 units (SEC Form 4)
Latest HQL
- SEC Form N-CSRS filed by abrdn Life Sciences Investors Shares of Beneficial Interest
- ABERDEEN INVESTMENTS U.S. CLOSED-END FUNDS ANNOUNCE RESULTS OF ANNUAL MEETING OF SHAREHOLDERS
- Certain Aberdeen Investments U.S. Closed-End Funds Declare Distribution Dates and Amounts
- Aberdeen Investments U.S. Closed-End Funds Announce Distribution Payment Details
- Certain Aberdeen Investments U.S. Closed-End Funds Declare Distribution Dates and Amounts
- Aberdeen Investments U.S. Closed-End Funds Announce Distribution Payment Details
- SEC Form 3 filed by new insider Reilly Heather Carter
- Director Pittard Christian bought $133,755 worth of shares (7,923 units at $16.88) (SEC Form 4)
- SEC Form N-CSR filed by abrdn Life Sciences Investors Shares of Beneficial Interest
- SEC Form N-CEN filed by abrdn Life Sciences Investors Shares of Beneficial Interest